Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Comparison of Ultrasound Features of Major Salivary Glands in Sarcoidosis, Amyloidosis, and Sjögren's Syndrome.

Law ST, Reza Jafarzadeh S, Govender P, Sun X, Sanchorawala V, Kissin EY.

Arthritis Care Res (Hoboken). 2019 Jul 15. doi: 10.1002/acr.24029. [Epub ahead of print]

PMID:
31309727
2.

A new era of amyloidosis: the trends at a major US referral centre.

Staron A, Connors LH, Ruberg FL, Mendelson LM, Sanchorawala V.

Amyloid. 2019 Jul 15:1-5. doi: 10.1080/13506129.2019.1640672. [Epub ahead of print]

PMID:
31306033
3.

Prevalence and Prognostic Value of D-dimer Elevation in Patients with AL Amyloidosis.

Pudusseri A, Sanchorawala V, Sloan JM, Bever KM, Doros G, Kataria S, Sarosiek S.

Am J Hematol. 2019 Jul 11. doi: 10.1002/ajh.25576. [Epub ahead of print]

PMID:
31292986
4.

Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature.

Qualls DA, Lewis GD, Sanchorawala V, Staron A.

Am J Transplant. 2019 Jun 17. doi: 10.1111/ajt.15499. [Epub ahead of print]

PMID:
31207062
5.

Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis.

Sanchorawala V, Doros G, Shelton AC.

Am J Hematol. 2019 Jul;94(7):E194-E196. doi: 10.1002/ajh.25497. Epub 2019 May 3. No abstract available.

PMID:
31020691
6.

Early Detection of Multiorgan Light Chain (AL) Amyloidosis by Whole Body 18F-florbetapir PET/CT.

Ehman EC, El-Sady MS, Kijewski MF, Khor YM, Jacob S, Ruberg FL, Sanchorawala V, Landau H, Yee AJ, Bianchi G, Di Carli MF, Falk RH, Hyun H, Dorbala S.

J Nucl Med. 2019 Apr 6. pii: jnumed.118.221770. doi: 10.2967/jnumed.118.221770. [Epub ahead of print]

PMID:
30954943
7.

Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

Sanchorawala V.

Blood Adv. 2019 Jan 22;3(2):216-218. doi: 10.1182/bloodadvances.2018021261. No abstract available.

8.

High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators.

Phull P, Sanchorawala V, Brauneis D, Sloan JM, Siddiqi OK, Quillen K, Sarosiek S.

Bone Marrow Transplant. 2019 Jan 21. doi: 10.1038/s41409-019-0440-5. [Epub ahead of print]

PMID:
30664726
9.

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.

Gupta VK, Brauneis D, Shelton AC, Quillen K, Sarosiek S, Sloan JM, Sanchorawala V.

Biol Blood Marrow Transplant. 2019 May;25(5):e169-e173. doi: 10.1016/j.bbmt.2019.01.007. Epub 2019 Jan 11.

PMID:
30639823
10.

Long-term outcome of kidney transplantation in AL amyloidosis.

Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, Havasi A.

Kidney Int. 2019 Feb;95(2):405-411. doi: 10.1016/j.kint.2018.09.021. Epub 2018 Dec 21.

PMID:
30580886
11.

Bortezomib ocular toxicities: Outcomes with ketotifen.

Dennis M, Maoz A, Hughes D, Sanchorawala V, Sloan JM, Sarosiek S.

Am J Hematol. 2019 Mar;94(3):E80-E82. doi: 10.1002/ajh.25382. Epub 2019 Jan 3. No abstract available.

PMID:
30575098
12.

Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis.

McCausland KL, Quock TP, Rizio AA, Bayliss MS, White MK, Guthrie SD, Sanchorawala V.

Br J Haematol. 2019 Jun;185(5):998-1001. doi: 10.1111/bjh.15693. Epub 2018 Nov 22. No abstract available.

PMID:
30467849
13.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA.

Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. Review.

PMID:
30361521
14.

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.

Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V.

Blood. 2019 Jan 17;133(3):215-223. doi: 10.1182/blood-2018-06-858951. Epub 2018 Oct 17.

PMID:
30333122
15.

A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics.

Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ.

Amyloid. 2018 Sep;25(3):148-155. doi: 10.1080/13506129.2018.1489228. Epub 2018 Jul 21.

PMID:
30032658
16.

Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.

Nguyen VP, Rosenberg A, Mendelson LM, Comenzo RL, Varga C, Sanchorawala V.

Amyloid. 2018 Sep;25(3):156-159. doi: 10.1080/13506129.2018.1490261. Epub 2018 Jul 21.

PMID:
30032640
17.

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, Sarosiek S, Sanchorawala V.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1823-1827. doi: 10.1016/j.bbmt.2018.06.018. Epub 2018 Jun 20.

PMID:
29933072
18.

Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation.

Sarosiek S, Quillen K, Sloan JM, Brauneis D, Sanchorawala V.

Blood. 2018 Aug 16;132(7):755-757. doi: 10.1182/blood-2018-03-838672. Epub 2018 Jun 14. No abstract available.

PMID:
29903887
19.

High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers.

White PS, Phull P, Brauneis D, Sloan JM, Quillen K, Sarosiek S, Sanchorawala V.

Bone Marrow Transplant. 2018 Dec;53(12):1593-1595. doi: 10.1038/s41409-018-0242-1. Epub 2018 Jun 8. No abstract available.

PMID:
29884854
20.

Echocardiography and Survival in Light Chain Cardiac Amyloidosis: Back to Basics.

Siddiqi OK, Sanchorawala V, Ruberg FL.

Circ Cardiovasc Imaging. 2018 May;11(5):e007826. doi: 10.1161/CIRCIMAGING.118.007826. No abstract available.

PMID:
29752394
21.

Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients.

Pudusseri A, Smith I, Sarnacki D, Brauneis D, Shelton A, Sanchorawala V, Sloan JM, Sarosiek S, Quillen K.

Transfus Apher Sci. 2018 Jun;57(3):411-415. doi: 10.1016/j.transci.2018.04.025. Epub 2018 Apr 26.

PMID:
29731423
22.

Once AL amyloidosis: not always AL amyloidosis.

Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V.

Amyloid. 2018 Jun;25(2):139-140. doi: 10.1080/13506129.2018.1449104. Epub 2018 Mar 8. No abstract available.

PMID:
29516761
23.

Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation.

Havasi A, Doros G, Sanchorawala V.

Am J Hematol. 2018 May;93(5):E129-E132. doi: 10.1002/ajh.25066. Epub 2018 Feb 24. No abstract available.

24.

Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).

Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S.

Amyloid. 2018 Mar;25(1):62-67. doi: 10.1080/13506129.2018.1436048. Epub 2018 Feb 9.

25.

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.

Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V.

Amyloid. 2018 Mar;25(1):1-7. doi: 10.1080/13506129.2017.1411796. Epub 2018 Jan 5.

PMID:
29303358
26.

Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis.

Nguyen VP, Brauneis D, Kaku M, Sloan JM, Sarosiek S, Quillen K, Shelton AC, Sanchorawala V.

Bone Marrow Transplant. 2018 Mar;53(3):371-373. doi: 10.1038/s41409-017-0048-6. Epub 2017 Dec 21. No abstract available.

PMID:
29269794
27.

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples.

White MK, McCausland KL, Sanchorawala V, Guthrie SD, Bayliss MS.

Patient Relat Outcome Meas. 2017 Dec 7;8:157-167. doi: 10.2147/PROM.S146849. eCollection 2017.

28.

Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.

Ding Y, Francis J, Gautam A, Pelletier L, Sanchorawala V, Quillen K.

Clin Nephrol. 2018 Apr;89(4):252-259. doi: 10.5414/CN109278.

PMID:
29208204
29.

High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.

Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember LM, Sanchorawala V.

Biol Blood Marrow Transplant. 2018 Jan;24(1):127-132. doi: 10.1016/j.bbmt.2017.08.031. Epub 2017 Sep 1.

30.

A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time.

Sanchorawala V, McCausland KL, White MK, Bayliss MS, Guthrie SD, Lo S, Skinner M.

Br J Haematol. 2017 Nov;179(3):461-470. doi: 10.1111/bjh.14889. Epub 2017 Aug 29.

31.

The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution.

Arun M, Brauneis D, Doros G, Shelton AC, Sloan JM, Quillen K, Ruberg FL, Sanchorawala V, Varga C.

Bone Marrow Transplant. 2017 Sep;52(9):1349-1351. doi: 10.1038/bmt.2017.148. Epub 2017 Jul 24. No abstract available.

PMID:
28737773
32.

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.

Browning S, Quillen K, Sloan JM, Doros G, Sarosiek S, Sanchorawala V.

Blood. 2017 Sep 14;130(11):1383-1386. doi: 10.1182/blood-2017-06-788729. Epub 2017 Jul 11. No abstract available.

33.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

34.

Transbronchial biopsies safely diagnose amyloid lung disease.

Govender P, Keyes CM, Hankinson EA, O'Hara CJ, Sanchorawala V, Berk JL.

Amyloid. 2017 Mar;24(1):37-41. doi: 10.1080/13506129.2017.1301917. Epub 2017 Apr 10.

35.

The six-minute walk test in patients with AL amyloidosis: a single centre case series.

Pulido V, Doros G, Berk JL, Sanchorawala V.

Br J Haematol. 2017 May;177(3):388-394. doi: 10.1111/bjh.14586. Epub 2017 Mar 24.

PMID:
28340285
36.

A Woman in Her 40s With Headache and New-Onset Seizures.

Graham MS, Pudusseri A, Helgager J, Narendra DP, De Girolami U, Pinkus GS, Sanchorawala V, Miyawaki E.

JAMA Neurol. 2017 Apr 1;74(4):476-480. doi: 10.1001/jamaneurol.2016.2961.

PMID:
28241235
37.

Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis.

Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL.

Eur Heart J Cardiovasc Imaging. 2017 Sep 1;18(9):1057-1064. doi: 10.1093/ehjci/jew298.

PMID:
27965280
38.

Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis.

Uwumugambi NA, Sanchorawala V, Shelton AC, Stern L, Gordon CE.

Am J Kidney Dis. 2017 Feb;69(2):317-319. doi: 10.1053/j.ajkd.2016.07.037. Epub 2016 Oct 22.

PMID:
27780577
39.

Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients.

Shu J, Lo S, Phillips M, Sun F, Seldin DC, Berenbaum I, Berk JL, Sanchorawala V.

Amyloid. 2016 Sep;23(3):188-193. Epub 2016 Jul 27.

PMID:
27460276
40.

Penile ulcers complicating systemic AL amyloidosis: a case report.

Arun M, Sloan SB, Shelton A, Sanchorawala V.

Amyloid. 2016 Sep;23(3):203-204. Epub 2016 May 17. No abstract available.

PMID:
27187183
41.

Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.

Prokaeva T, Spencer B, Sun F, O'Hara RM, Seldin DC, Connors LH, Sanchorawala V.

Amyloid. 2016 Dec;23(4):214-220. Epub 2016 Sep 28.

PMID:
27677679
42.

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL.

Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15. Review.

43.

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial.

Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC.

Blood. 2016 Aug 25;128(8):1059-62. doi: 10.1182/blood-2016-04-710822. Epub 2016 Jul 5.

44.

Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.

Havasi A, Stern L, Lo S, Sun F, Sanchorawala V.

Am J Hematol. 2016 Oct;91(10):E458-60. doi: 10.1002/ajh.24464. Epub 2016 Jul 14. No abstract available.

45.

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.

Dittus C, Uwumugambi N, Sun F, Sloan JM, Sanchorawala V.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1729-1732. doi: 10.1016/j.bbmt.2016.05.027. Epub 2016 Jun 11.

46.

Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Lee SY, Meehan RS, Seldin DC, Sloan JM, Quillen K, Shelton A, Brauneis D, Sanchorawala V.

Bone Marrow Transplant. 2016 Oct;51(10):1318-1322. doi: 10.1038/bmt.2016.132. Epub 2016 May 16.

PMID:
27183092
47.

David C Seldin, MD, PhD: scientist, clinician, teacher, gentleman, 1957-2015.

Sanchorawala V, Gale RP.

Bone Marrow Transplant. 2016 Mar;51(3):323. doi: 10.1038/bmt.2015.340. No abstract available.

PMID:
26931484
48.

Clinical presentation and treatment responses in IgM-related AL amyloidosis.

Sissoko M, Sanchorawala V, Seldin D, Sworder B, Angelino K, Broce M, Berk J, Sloan JM.

Amyloid. 2015;22(4):229-35. doi: 10.3109/13506129.2015.1092433. Epub 2015 Oct 21.

PMID:
26488936
49.

Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

Bever KM, Masha LI, Sun F, Stern L, Havasi A, Berk JL, Sanchorawala V, Seldin DC, Sloan JM.

Haematologica. 2016 Jan;101(1):86-90. doi: 10.3324/haematol.2015.133900. Epub 2015 Oct 9.

50.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC.

Blood. 2015 Nov 12;126(20):2345-7. doi: 10.1182/blood-2015-08-662726. Epub 2015 Oct 6. No abstract available.

Supplemental Content

Loading ...
Support Center